Industries de la santé
Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression
![Envoyer](/templates/yoo_flux/images/emailButton.png)
![Imprimer](/templates/yoo_flux/images/printButton.png)
![PDF](/templates/yoo_flux/images/pdf_button.png)
16 Septembre 2014
Brain shrinkage is associated with a loss of physical and cognitive function and occurs at a faster rate in people with MS than those without the disease |New data showed patients who had the highest rates of brain shrinkage (brain volume loss) at two years had a higher risk of disability progression at four years
Separate analyses showed that patients continuously treated with Gilenya...